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In order to elucidate the relative importance of oestrogen receptor (ER)a,E R b and an ERb variant (ERb2/bcx) in the response of
breast cancers to tamoxifen, tumour levels of each receptor were assessed in 36 patients before and after 3 months of neoadjuvant
treatment with tamoxifen (20mg daily). All patients were postmenopausal women presenting with large ERa-positive breast cancers.
Clinical response to treatment was assessed by tumour volume changes as determined from sequential ultrasounds and pathological
response by comparison of the tumour morphology before and after treatment. Of 33 cases, 23 (70%) were classified as having a
clinical response and 16 (48%) as having a response pathologically. All tumours stained positively for ERa and ERb and 15 out of 33
(45%) for ERb2/bcx. There were no significant differences in quantitative expression of any receptor between tumours that
subsequently responded and that did not, whether response was assessed clinically or pathologically. Tamoxifen treatment was
associated with a decrease in ERa, but an increase was the most frequent change (17 out of 33) in ERb, and no consistent change was
evident in staining of the ERb2/bcx variant. In summary, ERb1 and ERb2/bcx variant protein are detected in ERa-positive breast
tumours but their expression is not associated with a response to tamoxifen. Differential changes in ERa and ERb were seen with
treatment.
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The anti-oestrogen tamoxifen has a central place in the treatment
of breast cancer. However, many tumours appear refractory to the
drug and there is a need to discover predictive markers that can
accurately identify hormone responsive tumours. In this setting,
oestrogen receptor (ER)a is the single most informative marker,
receptor-negative tumours rarely benefiting from endocrine
therapy (Miller, 1996). However, although responses are largely
restricted to ERa-positive tumours, only between 60 and 70% of
these cancers shrink with treatment. Hence, there is a requirement
for additional markers to improve discrimination. Interest in the
role played by receptors for oestrogen in breast cancer was
revitalised by the discovery of a second form of oestrogen receptor,
now named ERb (Kuiper et al, 1996; Mosselman et al, 1996). In
particular, it is notable that cell-based studies have suggested that
coexpression of ERb in ERa-positive cells may modulate the ability
of the cells to respond to oestrogens (Hall and McDonnell, 1999;
Strom et al, 2004) and studies using mice with targeted disruption
of the ERb gene have endorsed this idea (Weihua et al, 2000;
Lindberg et al, 2003). In the light of these observations, the
suggestion has been made that the level of expression of ERb in
ERa-positive breast cancers might modify tumour response to
anti-oestrogenic action. This could account for resistance to
endocrine therapy but it remains a topic of debate (reviewed by
Warner et al, 2000; Speirs et al, 2004). The situation is complicated
further by the identification of a number of splice variant isoforms
of the human ERb gene (Moore et al, 1998), the mRNAs for which
have been detected in breast cancer tissues and breast cancer cell
lines (Fuqua et al, 1999; Speirs et al, 2000; Poola et al, 2002a,b).
Studies in vitro have suggested that ERb isoforms with deletions of
selected exons, or with alternative splicing at the C-terminus, may
act as dominant-negative inhibitors of full-length ERa and/or ERb
(Ogawa et al, 1998b; Inoue et al, 2000; Peng et al, 2003).
An antibody specific for full-length ERb, hereafter referred to as
ERb1, has been used previously to delineate the pattern of
expression of this isoform of the receptor in breast cancer biopsies
(Saunders et al, 2002b; Carder et al, 2005). The present paper has
taken advantage of the development of a monoclonal specific for
the ERbcx/b2 splice variant (Saunders et al, 2002a) to determine
whether expression of this isoform influences response to anti-
oestrogen therapy as has been claimed by others (Saji et al,
2002a,b).
MATERIALS AND METHODS
Patients
All patients were referred between 1992 and 1995 to the Edinburgh
Breast Unit and had histologically confirmed diagnosis of breast
cancer (Miller et al, 1999). The women were postmenopausal, aged
between 56 and 80 years, had a large (43cm) primary tumour
Received 25 August 2005; revised 8 February 2006; accepted 27
February 2006; published online 18 April 2006
*Correspondence: Professor PTK Saunders; E-mail: p.saunders@ed.ac.uk
British Journal of Cancer (2006) 94, 1333–1338
& 2006 Cancer Research UK All rights reserved 0007– 0920/06 $30.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
swith an ER histoscore 480 (equivalent to X5 Allred score –
although a single case was subsequently graded as score 4 by the
research lab) or a biochemical score of 420fmolmg protein
 1 (on
the initial biopsy taken for diagnosis) and had no evidence of
distant metastatic disease. None had received prior treatment with
hormonal agents for breast cancer or were taking hormone
preparations at the time of study. Tumour size was monitored
clinically (by calipers) and by breast ultrasound before and at
monthly intervals during treatment. Therapy comprised daily
administration of tamoxifen (25mg) for 3 months; four patients
electively continued on therapy for a further 3 months. A total of
72 consecutive patients were entered into the study; however, data
are presented in 33 for ERa and ERb1 and the ERb2/bcx variant
because in the remainder either pre- and/or post-treatment
tumour blocks were exhausted by use for other studies. The
demographics of the investigated cases were not different from the
recruited population. The studies were performed with the
patients’ informed consent and ethical permission (LREC nos.
2001/8/80 and 2001/8/81).
Clinical response
Clinical response was usually based on change in tumour volume
between pretreatment and 3-month values; however, assessment
was made at 6 months in those patients electing for extended
treatment. Ultrasound measurement of three orthogonal tumour
diameters produced an estimate of tumour volume. Reduction in
tumour volumes 425% was regarded as evidence of tumour
response; those 450% were categorised as major response
(Forouhi et al, 1994).
Pathological response
Histological sections from the initial biopsy and the final surgical
excision were assessed for decrease in cancer cellularity and
increase in fibrosis gland formation. Where this occurred, the
tumour was classified as having a pathological response, and where
clear changes in cellularity and/or fibrosis were not apparent, the
tumour was graded as no pathological response.
Tumour
Samples of each breast cancer was obtained by biopsy (before
treatment) and by definite surgery (wide local excision or
mastectomy) after treatment. Tumours were fixed in 10% neutral
buffered formaldehyde for 16–24h, then stored in 70% (wv
–1)
ethanol before processing into paraffin wax at the Department of
Pathology using standard procedures.
Antibodies
The anti-hERa mouse monoclonal antibody (code 1D5) was
obtained from Dako (Cambridge, UK). Monoclonal antibodies
specific for C-terminal peptides within wild-type human ERb
(hERb1, wild type; accession AB006590; Ogawa et al, 1998a;
Serotec UK MCA1974S) as well as one of the variant isoforms of
hERb known as hERb2/bcx (accession AB006589; Moore et al,
1998; Ogawa et al, 1998b; Serotec UK, MCA 2279S) were prepared
using standard methods as described previously (Saunders et al,
2000, 2002a). Specificity for the ERb isotype to which they were
directed has been confirmed on Western blots using recombinant
proteins (see Figure 2 in Saunders et al, 2002a). Neither antibody
showed any crossreactivity against ERa (Saunders et al, 2002a).
These antibodies have been used previously to determine the
patterns of expression of ERb1 in cancers of the breast (Saunders
et al, 2002b; Carder et al, 2005) and prostate (Torlakovic et al,
2002) as well as in a variety of non-malignant adult tissues
(Saunders et al, 2000, 2002a; Critchley et al, 2002; Gaskell et al,
2003).
Immunohistochemistry
Sections (4mm) were mounted on Superfrost coated slides (BDH,
Poole, Dorset, UK), dewaxed and rehydrated in gradient alcohols
and distilled water before staining with specific antibodies as
outlined below.
Anti-ERa All staining for ERa was carried out in the Pathology
Department of the Western General Hospital. An endogenous
biotin block was carried out by applying 100ml egg white blocking
solution for 30min. Anti-ERaDako was diluted 1 in 50 in biotin
diluent for primary antibodies (PBS, goat serum and d-biotin), and
applied to the sections for 60min at room temperature. The
secondary antibody, biotinylated anti-mouse Ig (Vector Labora-
tories, Peterborough, Cambridgeshire, UK) was diluted 1:2000 in
‘background reducing diluent’ (Dako) and applied to the sections
for 30min at room temperature. The tertiary system (ABC-HRP,
Dako) was applied as per the manufacturer’s instructions for
30min at room temperature. The tissue was visualised by
immersing sections in 3,30-diaminobenzidine tetrahydrochloride
(DAB) for 5min. Sections were counterstained using Mayers
haematoxylin (Sigma-Aldrich, Poole, Dorset, UK), dehydrated
through gradient alcohols and mounted.
Anti-ERb Tissue sections were dewaxed in Histoclear (National
Diagnostics, Atlanta, GA, USA) and rehydrated in descending
grades of alcohol to dH2O. Antigen retrieval was carried out by
pressure cooking in 0.05 M glycine 0.01% EDTA pH 3.5 for 3min
setting 2 (Tefal, Nottingham, UK) and sections left to stand
undisturbed for 20min. Sections were blocked for 30min in
normal rabbit serum (NRS; Diagnostics Scotland, Edinburgh,
Scotland, UK) diluted 1:4 in TBS containing 5% BSA (NRS/TBS/
BSA), rinsed briefly in TBS and an avidin–biotin block performed
using reagents from Vector (Petersborough, UK). Anti-ERb
antibodies were diluted in NRS/TBS (ERb1, 1 in 20; ERbcx/b21
in 40) and incubated on sections overnight at 41C. Sections were
washed twice for 5min each in TBS and incubated with
biotinylated rabbit anti-mouse immunoglobulin (Dako) diluted
1:500 in NRS/TBS/BSA. Bound antibodies were visualised by
incubation with DAB (liquid DAB cat K3468, Dako); the DAB was
added to sections at 8s intervals and the colour allowed to develop
for exactly 3min (ERb1) or 5min (ERb2/bcx). Control sections
previously used to determine the dilutions of antibodies were
included in all experimental runs. Sections were counterstained
with haematoxylin.
Images were captured using an Olympus Provis microscope
(Olympus Optical Co, London, UK) equipped with a Kodak
DCS330 camera (Eastman Kodak Co, Rochester, NY, USA).
Quantitation of immunohistochemical staining
Quantitation was based on a scoring system reported in detail
previously (Allred et al, 1998; Leake et al, 2000). This method is
based on a composite additive score of intensity 0–3 and the
proportion of malignant epithelial cells staining 0–5. This gives a
range of 0–8 for each tissue. Statistical analysis was carried out
using the Wilcoxon matched-pairs signed-ranks test, as this is more
sensitive than the Student’s t-test for small numbers of samples.
RESULTS
Response
Of the 33 patients studied, 23 (70%) were classified as having a
clinical response and 16 (48%) as having a response in tumour
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spathology. Although the majority of clinical responders/non-
responders had corresponding changes in tumour pathology, one
tumour that did not change in tumour volume with treatment
showed significant changes in tumour morphology; conversely,
eight tumours shrinking clinically with treatment did not change
their morphological appearance.
Oestrogen receptor a
All patients were required to have ERa-positive tumour in order to
be eligible for the study. There was no quantitative difference in
the initial staining score of tumours that either responded or did
not, clinically or morphologically (data not shown). Median
(range) was 7 (6–8) for responding tumours and 7 (4–8) for
non-responders (Table 1A).
Comparison of biopsies taken before and during treatment with
tamoxifen showed that ERa category scores decreased in all but six
tumours (five tumours were unchanged and one increased).
Although only one score fell to 0, the difference between pre-
and treated tumour was highly significant (Po0.0001 by paired
Wilcoxon test). No significant differences in change of score were
apparent between tumours that responded and that did not,
whether response was assessed clinically or by morphology
(Table 1).
Oestrogen receptor b1
All tumours stained positively with scores ranging from 5 to 8.
Although the median value was similar in cancers responding and
not responding clinically (median 7, range 5–8 in responding
tumours, and median 7, range 6–8 in non-responding cancers)
because of the difference in the distribution of values, levels were
significantly higher in non-responding tumours (P¼0.03 by
paired Wilcoxon test). The levels of ERb1 were not significantly
different in tumours that morphologically changed with treatment
as compared with those that did not. There was no correlation
between ERb1 and ERa scores and expressing results as the ratio of
ERa to ERb1 failed to increase discrimination between responding
and non-responding tumours (Table 2).
In contrast to ERa, tamoxifen treatment tended to be associated
with an increase in the staining intensity of ERb1, with 17 of 33
having a higher staining score after treatment. This difference in
the staining pattern of ERb1 with treatment is significantly
different from that observed in ERa (P¼0.001). However, the
pattern of change in the ERb1 score with treatment did not differ
according to response, whether this was assessed clinically or by
tumour pathology.
Oestrogen receptor b2/bcx splice variant
Expression of the ERb2/bcx variant was detected by immunohis-
tochemistry in 15 of 33 tumours (45%). Before therapy, the level of
expression of ERb2/bcx did not relate to expression of ERa or
ERb1, and examples of divergent results are shown in Figure 1.
Note that as ERb1 immunoexpression was found in all tumours,
55% were ERb1 positive/ERb2/bcx negative. There was no
difference in the status/level of expression of ERb2/bcx variant
between tumours responding to and those that did not to
tamoxifen (Table 3). Expressing results as a ratio with ERa or
ERb1 failed to increase discrimination between responding and
non-responding tumours (results not shown).
Treatment with tamoxifen resulted in decreased expression of
ERb2/bcx in 11 cases, increased expression in six tumours and no
changes in 16. Changes in expression were not related to response
or to changes in ERa and ERb1 (Figure 2).
Table 1 Oestrogen receptor a
(A) Immunohistochemical score in tumours responding (Resp) and
not responding (Non-R) to tamoxifen
a
Score 4 6 7 8
Total 1 2 17 13
Resp (Clin) 1 13 9
Non-R (Clin) 1 1 4 4
Resp (Path) 1 10 5
Non-R (Path) 1 1 7 8
(B) Change in immunohistochemical score with tamoxifen
treatment
a
Decrease No change Increase
Total 27 5 1
Clin Resp 18 4 1
Clin Non-R 9 1 0
Path Resp 12 3 1
Path Non-R 15 2 0
aNo significant differences between responding and non-responding tumours.
Table 2 Oestrogen receptor b1 (wild type)
(A) Immunohistochemical score in tumours responding (Resp) and
not responding (Non-R) to tamoxifen
a
Score 5 6 7 8
Total 1 8 19 5
Resp (Clin) 1 7 14 1
Non-R (Clin) 0 1 5 4
Resp (Path) 0 6 8 2
Non-R (Path) 1 2 11 3
(B) Change in immunohistochemical score with tamoxifen
treatment
b
Decrease No change Increase
Total 8 8 17
Resp (Clin) 5 4 14
Non-R (Clin) 3 4 3
Resp (Path) 4 5 7
Non-R (Path) 4 3 10
aSignificant difference between tumours responding and not responding clinically,
Po0.015 by w
2 test for trends.
bNo significant differences between responding and
not responding tumours.
ER2 ER1
Patient A
Patient B
Figure 1 In breast cancer biopsies, ERb2/bcx immunostatus did not
parallel that of ERb1. Results from two patients before therapy are shown.
Note that in patient A, the level of expression of ERb1bERb2/bcx,
whereas in patient B, ERb1&ltpERb2/bcx. Magnifications  40.
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sDISCUSSION
We have used well-characterised monoclonal antibodies (Critchley
et al, 2002; Saunders et al, 2002a) to compare the pattern of
expression of two isoforms of ERb, namely the full-length
functional receptor (ERb1) and the ERb2/bcx variant (Moore
et al, 1998; Ogawa et al, 1998b). Oestrogen receptor b1 contains a
functional steroid binding pocket (Pike et al, 1999), an intact AF-2
domain capable of recruiting coactivators (Klinge, 2000) and is
capable of inducing gene transcription in vitro (Paech et al, 1997;
Barkhem et al, 1998; Sierens et al, 2004). In contrast, ERb2/bcx
lacks 61 amino acids normally found at the C-terminus of ERb1
and instead contains novel 27 amino acids that do not encode a
functional AF-2 domain (Ogawa et al, 1998b). Studies in vitro have
shown that ERb2/bcx-containing constructs do not bind oestradiol
and that neither can they induce gene expression via oestrogen
response elements (EREs) in reporter assays (Ogawa et al, 1998b;
Peng et al, 2003; Sierens et al, 2004). Interest in determining
whether ERb2/bcx is expressed in breast and other cancers has
been fuelled by studies using transfected cells that have claimed
that coexpression of ERb2/bcx with ERa results in reduced
activation of ERE-containing reporter constructs (Ogawa et al,
1998b; Peng et al, 2003).
In the current study, we did not find any correlation between the
intensity of immunoexpression of ERb1 and ERb2/bcx in breast
cancer biopsies taken before treatment, with a higher proportion
of the tissues being immunopositive for ERb1 than for ERb2/bcx.
This finding was unexpected as both the proteins are encoded by
the same gene and are identical in sequence apart from alternative
splicing of alternative eighth exons. We have previously noted
differences in the pattern of expression of ERb1 and ERb2/bcx in
non-malignant tissues including the testis and endometrium
(Critchley et al, 2002; Saunders et al, 2002a) and therefore do
not believe that this finding is associated with the development of
malignancy although it does raise questions as to the mechanisms
controlling splicing of the human ERb gene. We detected ERb2/
bcx protein in 45% of the tumours. In other studies in which
expression of ERb2/bcx has been assessed using different ERb2/
bcx-specific antibodies, the protein has been detected in 48% (Saji
et al, 2002b; Palmieri et al, 2004) or 56% (Omoto et al, 2002) of the
tissues examined, which is in general agreement with our own
findings. Comparison with other studies that have reported the
incidence of ERb immunostaining is not possible because they
used antibodies that would not discriminate between ERb1 and
ERb2/bcx variants (Jarvinen et al, 2000; Skliris et al, 2001).
Functional studies have previously claimed that the agonist
activity of tamoxifen was ERa dependent (Watanabe et al, 1997).
However, a recent study in which the conformations adopted by
ERa and ERb following binding to tamoxifen were investigated has
resulted in a revised model for binding that includes interactions
with both ERa and ERb (Heldring et al, 2004). It is notable that in
the current study, tamoxifen treatment had an apparent impact on
the levels of expression of both ERa and ERb, but that the effects
were opposite to each other, with levels of ERa declining and those
of ERb1 increasing.
These cell-based studies provide a rationale for considering
whether the expression of ERb1 and/or ERb2/bcx in malignant
cells within the breast can influence the response of the tissue to
therapy with tamoxifen. Although there is a general consensus that
the presence of ERa predicts response to tamoxifen (ERa-negative
tumours rarely respond), the literature relating to ERb and
response to tamoxifen is confusing and conflicting. In part, this
is because studies have been performed in two different settings,
giving tamoxifen either as an adjuvant to surgery and measuring
recurrence rates/times (Murphy et al, 2002; Davies et al, 2004;
Esslimani-Sahla et al, 2004; Hopp et al, 2004; O’Neill et al, 2004) or
as neoadjuvant treatment and monitoring changes in the size of
the primary tumours. In general, the latter studies are more
Table 3 Oestrogen receptor b2/bcx (variant)
(A) Immunohistochemical score in tumours responding (Resp) and
not responding (Non-R) to tamoxifen
a
Score 0 4 5 6
Total 18 4 9 2
Resp (Clin) 12 3 7 1
Non-R (Clin) 6 1 2 1
Resp (Path) 7 1 7 1
Non-R (Path) 11 3 2 1
(B) Change in immunohistochemical score with tamoxifen
treatment
a
Decrease No change Increase
Total 11 16 6
Resp (Clin) 8 10 5
Non-R (Clin) 3 6 1
Resp (Path) 5 8 3
Non-R (Path) 6 8 3
aNo significant differences between responding and non-responding tumours.
Pre Post
1
2
1
2
AB
CD
EF
GH
Figure 2 Immunohistochemical localisation of ERb proteins to breast
biopsies obtained before and after treatment with tamoxifen. Results for
ERb1( A, B, E, F) and the ERb2/bcx variant (C, D, G, H) are shown for
two patients only one of whom (A–D) showed a positive clinical response
to therapy. In both patients, ERb1-positive malignant cells were present
before treatment (A, E), but whereas immunoexpression was reduced in
the patient who responded to therapy (compare A and B) there was no
reduction in expression in the other patient who did not exhibit a clinical
response (compare D with F). In both patients, expression of ERb2/bcx
was reduced (compare C and D; G and H). Magnifications,  40.
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sapplicable to tumour sensitivity to therapy, as recurrence in the
adjuvant setting is determined not only by response to systemic
treatment but also by the extent of micrometastatic disease and
inherent aggressiveness of the tumour. In this respect, the most
substantive neoadjuvant studies to date examining effects of the
closely related anti-oestrogen, toremifene, in 38 cases of preopera-
tively and 20 cases of postoperatively indicated that, as in the
present study, response was independent of ERb levels or changes
(Cappelletti et al, 2004). Two other studies have investigated ERb2/
bcx. One reported 23 patients who were treated neoadjuvantly and
found a statistically significant association between the presence of
ERb2/bcx and response to tamoxifen (P¼0.04) but the group was
unusual in that all three ERa-negative tumours also responded to
treatment. The other study (Saji et al, 2002b) evaluated 18 cases
and found ERb2/bcx expression to be associated with less chance
of response to tamoxifen. Given that the present study failed to
find either a positive or a negative association between ERb2/bcx
and response to tamoxifen, it seems unlikely that ERb2/bcx will be
predictive of response in individual cases.
In the current study, although ERb1 protein was detected in all
tumours, there was no correlation between the levels in those that
responded to treatment and those that did not. Furthermore, there
was no difference in the status/level of expression of ERb2/bcx
between tumours responding to and those that did not to
tamoxifen. In conclusion, to date, there is as yet no consensus
among the different studies in which response to tamoxifen has
been correlated with expression of ERb and/or the ERb2/bcx
variant as to whether measuring ERb expression in ERa-positive
breast cancers is likely to be informative as regards response to
anti-oestrogen therapy.
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